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ABSTRACT    1	  
 2	  
G protein-coupled receptor kinase 2 (GRK2) has recently emerged as a negative modulator of insulin signalling. GRK2 3	  
downregulation improves insulin sensitivity and prevents systemic insulin resistance (IR). Cardiac GRK2 levels are increased in 4	  
human heart failure, while genetically inhibiting GRK2 leads to cardioprotection in mice. However, the molecular basis underlying the 5	  
deleterious effects of GRK2 up-regulation and the beneficial effects of its inhibition in the heart are not fully understood. Therefore, 6	  
we have explored the interconnections among a systemic IR status, GRK2 dosage and cardiac insulin sensitivity in adult (9 month-old) 7	  
animals. GRK2+/- mice display enhanced cardiac insulin sensitivity and mild heart hypertrophy with preserved systolic function. 8	  
Cardiac gene expression is reprogrammed in these animals, with increased expression of genes related to physiological hypertrophy, 9	  
while the expression of genes related to pathological hypertrophy or to diabetes/obesity co-morbidities is repressed. Notably, we find 40	  
that cardiac GRK2 levels increase in situations where IR develops, such as in ob/ob mice or after high fat diet feeding. Our data 41	  
suggest that GRK2 downregulation/inhibition can help maintain cardiac function in the face of co-morbidities such as IR, diabetes or 42	  
obesity by sustaining insulin sensitivity and promoting a gene expression reprogramming that confers cardioprotection. 43	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1. INTRODUCTION 46	  
G protein-coupled receptor kinases (GRKs) were initially identified as serine-threonine kinases able to phosphorylate agonist-47	  
activated G protein-coupled receptors (GPCRs), triggering the binding of arrestins to the receptor, what impairs G protein coupling in 48	  
a process known as desensitization [1]. However, very recent findings suggest that the GRK2 isoform is also a key controller of 49	  
insulin receptor signaling [2]. GRK2 downregulation can prevent the development of metabolic disorders, modulating energy 0	  
expenditure and brown fat function [3] and also insulin actions in peripheral tissues [2]. Notably, GRK2+/- mice (expressing 50% less 1	  
protein than control littermates) show improved systemic insulin sensitivity, display enhanced activation of the insulin-mediated Akt 2	  
pathway in muscle, adipose tissue and liver, and are resistant to the induction of insulin resistance (IR) in three different mouse 3	  
models of this condition [2]. Remarkably, such differences in insulin sensitivity between wild type (WT) and GRK2 hemizygous mice 4	  
were noted in the adult stage but were not evident in young animals [2].  5	  
GRK2 has also been described to play a relevant role in cardiovascular physiopathology. Increased cardiac GRK2 levels have been 6	  
reported in patients with ischemic or idiopathic dilated cardiomyopathy, cardiac ischemia, hypertension, volume overload and left 7	  
ventricular hypertrophy [1, 4, 5]. Also, enhanced GRK2 expression induced by neurohormonal activation has been associated with 8	  
lower cardiac function and poorer prognosis in human heart failure (HF) and appears as an early event in maladaptive cardiac 9	  
remodelling in HF [5-7], altogether putting forward GRK2 as a relevant therapeutic target in this myocardial disease (reviewed in ref. 60	  
[6]). Consistently, genetic inhibition of GRK2 is cardioprotective in different animal models ([1, 5-8] and references therein), and 61	  
hemizygous GRK2 mice are hyper-responsive to catecholamines and display enhanced cardiac contractility and function, whereas 62	  
transgenic mice overexpressing different levels of this kinase show an impaired adrenergic cardiac response [9]). However, the 63	  
detailed molecular mechanisms and the relevant functional interactions underlying the deleterious effects of elevated GRK2 levels in 64	  
cardiac function and the beneficial effects of its inhibition remain to be fully established.  65	  
In principle, up-regulation of GRK2 in HF would further exacerbate the marked β-adrenergic desensitization observed in such 66	  
condition. However, chronic adrenergic activation appears to be more detrimental than beneficial for heart disease and, most 67	  
	   3	  
importantly, β-blockers represent a successful standard treatment for this disease. In this context, the fact that GRK2 inhibition acts in 68	  
a synergic manner with established β-blocker treatments (reviewed in [6, 7]) suggests these two therapeutic strategies must have 69	  
independent mechanisms of action. Thus, the functional impact of altered GRK2 levels might also be related to the interactions of this 0	  
protein with cellular partners other than β-adrenergic receptors [10]. 1	  
In this regard, adding to the data showing that GRK2 up-regulation inhibits insulin signaling in muscle or adipose tissue [2], recent 2	  
findings have suggested that cardiac-specific overexpression of GRK2 inhibits glucose uptake and promotes IR after myocardial 3	  
ischemia in young mice [11]. However, the potential interconnections among a systemic IR status, GRK2 levels and the cardiac 4	  
maladaptive remodeling linked to cardiac dysfunction have not been addressed to date. 5	  
In this report, we have characterized the activation of insulin signaling pathways, tissue remodeling in the heart	   and 6	  
cardioprotective gene expression patterns in young and adult WT and GRK2+/- mice. This experimental model allows us to explore the 7	  
consequences of a chronic, physiological-range change in GRK2 levels with age (a risk factor for the onset of most cardiovascular 8	  
pathologies) that would mimic the long sought pharmacological systemic inhibition of GRK2 as a potential drug target. In addition, 9	  
we have investigated the effect of systemic IR-promoting conditions on cardiac GRK2 levels and its impact on cardiac insulin 0	  
responses. Our data point at new molecular links between GRK2 up-regulation in IR-related situations and maladaptive cardiac 1	  
remodeling in the adult mouse heart. 2	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2. MATERIALS AND METHODS 6	  
 7	  
2.1 Animals 8	  
Experiments were performed on male wild type and hemizygous-GRK2 (GRK2+/-) mice maintained on the hybrid 129/SvJ 9	  
C57BL/6 background. The animals were bred and housed on a 12-hour light/dark cycle with free access to food and water. GRK2+/- 0	  
mice, as well as male leptin-deficient obese ob/ob mice (C57BL/6J-Lepob/Lepob) and their corresponding wild types (C57BL/6J, The 1	  
Jackson Laboratory, Bar Harbor, ME, USA) were fed ad libitum since weaning either on a normal chow diet (providing 13% of total 2	  
calories as fat, 67% as carbohydrate and 20% as protein; 2014S Rodent Maintenance Diet, Teklad, Harlan, Barcelona, Spain) or a high 3	  
fat diet (providing 45% of total calories as fat, 35% as carbohydrate and 20% as protein, Rodent Diet D12451, Research Diets, New 4	  
Brunswick, NJ, USA). Animals were maintained at a room temperature of 22±2 ºC on a 12:12 light-dark cycle (lights on at 08:00 am) 5	  
with a relative humidity of 50±10% and under pathogen-free conditions. All animal experimentation procedures conformed to the 6	  
European Guidelines for the Care and Use of Laboratory Animals (Directive 86/609) and approved by the Ethical Committees for 7	  
Animal Experimentation of the Universidad Autonoma de Madrid and the University of Navarra (protocols 013/08 and 041/08). 8	  
 9	  
2.2 Plasma membrane preparation and GLUT4 translocation quantification 0	  
Relative quantification of GLUT4 protein in the plasma membrane fraction was achieved by a subcellular fractionation method 1	  
modified from Rett K. et al [12]. Mice were injected intravenously in the tail vein with insulin (1 unit/kg of body weight). After 25 2	  
minutes, mice were sacrificed by cervical dislocation and hearts were homogenized using metal beads in a Tissue Lyser using cooled 3	  
buffer (200 mM Tris-HCl pH 7.5, 10mM EDTA, 255 mM Sucrose) with protease inhibitors (100 µM PMSF, 1 µM benzamidine, 10 4	  
µg/ml STI, 16 µU aprotinin, 10 µg/ml bacitracin). Lysates were centrifuged at 9000 x g for 20 minutes. The pellet (P1) was 5	  
resuspended in buffer, homogenized again and centrifuged at 200 x g for 20 minutes. The plasma membrane-enriched P2 was then 6	  
resuspended and homogenized in RIPA buffer (100 mM Tris-HCl pH 7.4, 600 mM NaCl, 2% Triton X-100, 0.2% sodium dodecyl 7	  
sulfate, 1% deoxycholate plus protease inhibitors) for Western Blot analysis. Protein content was quantified using the Lowry 8	  
procedure  and 40 µg of total protein were resolved on a 12% SDS-PAGE gel and transferred to a nitrocellulose membrane. Blots 9	  
shown here were probed with specific antibodies against GLUT4 (EMD Millipore, Darmstadt, Germany), Caveolin 3 (BD 0	  
Transduction Laboratories, Franklin Lakes, NJ, USA) and α-Tubulin (Santa Cruz Biotechnology, Dallas, TX, USA). 1	  
 2	  
2.3 Insulin treatments and Western Blots 3	  
Insulin (Actrapid®, Novo Nordisk, Bagsvaerd,  Denmark) solution in saline serum (1unit/kg body weight) was administered by tail 4	  
vein injection for acute cardiac insulin pathway activation analysis. After either 3 or 5 minutes, mice were sacrificed by cervical 5	  
dislocation and hearts were quickly collected, washed and frozen at -70 ºC. Heart tissue was homogenized using metal beads in a 6	  
Tissue Lyser using hypotonic buffer (20 mM Tris-HCl pH 7.5, 1 mM EDTA, 1 mM EGTA) completed with protease and phosphatase 7	  
inhibitors (100 µM PMSF, 1 µM benzamidine, 10 µg/ml STI, 16 µU aprotinin, 10 µg/ml bacitracin and Phosphatase Inhibitor Cocktail 8	  
-PhosSTOP, (Roche, Indianapolis, IN, USA)- following manufacturer´s protocol). Then 0.1% (v/v) Triton X-100 was added and the 9	  
samples were agitated for 1 h. at 4ºC, and centrifuged to measure supernatants protein content using the Lowry procedure. For 0	  
Western Blot analysis, typically 40 µg of total cardiac protein was resolved per lane on a 7.5% SDS-PAGE gel and transferred to a 1	  
nitrocellulose membrane. Blots were probed with specific antibodies against phospho-Akt (Ser473), Akt, phospho-p70S6K (Thr389), 2	  
phospho-ERK1/2 (Thr202/Tyr204) (Cell SignallingTechnology, Beverly Ma, USA ), p70S6K, phospho-IRS1 (Tyr896) (BD 3	  
	   5	  
biosciences,Franklin Lakes, NJ, USA), ERK-1, ERK-2, GRK2, Nucleolin (Santa Cruz Biotechnology, Dallas, TX, USA) ,GAPDH 4	  
(Abcam,Cambridge, UK) and IRS1-PH (kindly provided by Deborah J. Burks, Spain)	  [13].  5	  
 6	  
2.4 Cardiac morphometry 7	  
For the histological and morphometric analysis of the hearts, mice were anesthetized with isoflurane and an intracardiac injection 8	  
of cold KCl solution was used to stop the heart in diastole before the heart collection. Hearts were weighted for cardiac index 9	  
determination, and the medial section was fixed in formaldehyde and embedded in paraffin prior to transversal sectioning using a 0	  
microtome. Masson´s Trichrome staining was performed for the morphometric analysis and Syrius red staining for fibrosis 1	  
quantification. Images were analyzed using the AnalySIS® software (Soft Imaging System). 2	  
2.5 Echocardiography 3	  
 To measure global systolic cardiac function and left ventricular mass (LVM), echocardiography was performed in 9 month-old 4	  
WT and hemizygous GRK2 mice. Mice were anaesthetized by inhalation of isoflurane/oxygen (1.25%/98.75%) and examined by a 30 5	  
MHz transthoracic echocardiography probe. Images were obtained with Vevo 770 (VisualSonics, Toronto, Canada). The internal 6	  
diameter of the LV was measured in the short-axis view from M-mode recordings in end diastole and end systole and ejection fraction 7	  
(EF) and fractional shortening (FS) were calculated using the formulas as previously described [14]. 8	  
2.6 RNA isolation and microarray analysis 9	  
 mRNA from frozen heart tissue was extracted using metal beads (2 min, 30 Hz) in a Tissue Lyser and Fibrous Tissue RNeasy 0	  
Mini Kit, both from QIAGEN (Hilden, Germany). Three mice per condition were used for the gene expression profile analysis of 1	  
GRK2+/- and WT mice of 4 and 9 months of age. cDNA synthesis, labeling and microarray analysis were performed with the aid of the 2	  
Bioinformatics group at the National Center of Biotechnology (CNB, Madrid, Spain). Generation of double-stranded cDNA, 3	  
preparation and labelling of cRNA, hybridization to GeneChip® Mouse Genome 430 2.0 Arrays (Affymetrix, Santa Clara, CA, USA) 4	  
and washing was performed according to the protocol provided by Affymetrix. Probe sets were summarized using the LiMMA 5	  
algorithm. Results were analyzed and visualized using Researcher´s Digest software and FIESTA viewer respectively, as well as 6	  
Multiexperiment Viewer software (TM4 Microarray Software Suite).  7	  
2.7 Co-immunoprecipitation assays 8	  
Cell lysates obtained as previously described for Western Blot were quantified using the Lowry procedure. Next, 500 µg total protein 9	  
per lysate were incubated with 10 µl of either rabbit IgG or IRS1 antibody (Santa Cruz Biotechnology, Dallas, TX, USA) and 0.4 0	  
µg/µl BSA on a rotating shaker at 4°C overnight and 15 µl of Protein G-Sepharose (50% in lysis buffer) were added to each tube. 1	  
After 2 hours on a rotating shaker at 4°C, tubes were centrifuged at 14000 x g for 5 seconds and the pellets were washed with pre-2	  
chilled washing buffer (hypotonic-1% Triton) for 10 times (1ml each). Pellets were then boiled in 4x Laemmli loading buffer for 5 3	  
minutes and used for Western Blot analysis. Blots were probed with specific antibodies against IRS1-PH [13] and GRK2 (Santa Cruz 4	  
Biotechnology, Dallas, TX, USA). 5	  
 6	  
2.8 RT-PCR and microarray validation 7	  
	   6	  
 mRNA from heart tissue of at least 6 WT and 6 GRK2+/- mice was isolated as described before. RT-PCRs were performed by the 8	  
Genomic Facility at CBMSO using Light Cycler equipment (Roche, Indianapolis, IN, USA). Microarray validations were performed 9	  
using both commercial Taqman Gene Expression Assay probes (Applied Biosystems,Life Technologies, Grand Island, NY, USA) and 0	  
self-designed probes purchased from Sigma with Syber Green technology. qPCRs and statistical analysis of the data were performed 1	  
by the Genomic Facility at CBMSO using GenEx software. 2	  
2.9 Small-animal PET protocol  3	  
2-deoxy-2-[18F]-fluoro-D-glucose in isotonic saline solution was injected through the intravenous catheter of WT and GRK2+/- 4	  
adult mice to characterize heart glucose utilization in basal and after 5-min insulin stimulation. 90-minutes dynamic imaging was 5	  
performed with a piPET scanner and tomographic images were reconstructed using a three-dimensional ordered subset expectation 6	  
maximization algorithm as previously described [15] . Region of interest measurements were made on multiple axial slices of the 7	  
myocardium and tracer uptake was quantified as standardized uptake values normalized by injected dose and corrected for body 8	  
weight. 9	  
2.10 Statistics 0	  
Data were analyzed by one-way ANOVA, followed by a Bonferroni's post hoc analysis, or by unpaired t-testing when specified, as 1	  
appropriate. For all tests, P < 0.05 was considered statistically significant after Bonferroni corrections, if needed, and all data are 2	  
reported as means ± SEM. 3	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3. RESULTS  5	  
3.1 Decreased GRK2 levels correlate with enhanced cardiac insulin sensitivity 6	  
GRK2 can act as a negative modulator of insulin receptor signalling pathways, and adult GRK2+/- mice show improved systemic 7	  
insulin sensitivity and are resistant to the induction of IR in peripheral tissues [2]. In this context, we explored the possibility that 8	  
GRK2 dosage could modify heart insulin sensitivity in vivo in 9 month-old mice. The translocation to the plasma membrane of the 9	  
GLUT4 glucose transporter is a key early event in glucose uptake stimulated by insulin. As can be observed in Figure 1a, insulin-0	  
dependent GLUT4 translocation was significantly enhanced in adult GRK2 hemizygous mice, compared to wild-type animals, as 1	  
assessed by Western Blot analysis of membrane fractions of cardiac tissue. These results are in agreement with the increased 2	  
accumulation of labelled deoxyglucose in the hearts of GRK2+/- mice quantified by PET (Supplementary Figure 1S). A similar pattern 3	  
was observed for the rapid stimulation of Akt and its downstream target p70S6K kinase detected with specific phospho-antibodies 4	  
upon injection of insulin (Fig. 1b-e).  5	  
Of note, upstream insulin signalling events such as the amount of phospho-Tyrosine(Tyr896)IRS1 was increased in GRK2+/- hearts 6	  
after insulin stimulation while the activation status of the ERK cascade was not affected (Supplementary Fig. 1S b-d). Together, these 7	  
results demonstrate that the metabolic and pro-survival signals downstream of insulin were more potently activated in GRK2+/- hearts 8	  
than in WT mice.  9	  
3.2 GRK2+/- 9 month-old mice display mild, non-pathological heart hypertrophy  0	  
The modulation of the PI3K/Akt and the ERK pathways in the heart is shared by insulin, IGF-1 and hypertrophic agonists such as 1	  
angiotensin II. The PI3K/Akt cascade relates mostly to physiological hypertrophy, whereas MAPK signalling, together with PKC and 2	  
calcineurin/NFAT, participates in the development of the pathological hypertrophy typically induced by angiotensin II (reviewed in 3	  
ref. [16]).  4	  
We found that GRK2+/- mice showed a modest but significant increase in heart to body weight ratio and in the total cardiac area with 5	  
age compared to the change observed in WT animals (Fig. 2a and 2b). We also found an enhanced increase in cardiomyocyte diameter 6	  
in GRK2+/- animals (Fig. 2c), an established indicator of cardiac hypertrophy. No differences in these parameters were found at 4 7	  
months of age between WT and GRK2+/- animals. Echocardiographic analysis also revealed a certain degree of hypertrophy in the 9 8	  
month-old hemizygous mice, mainly referred to left ventricular mass (data not shown) in the absence of any alterations in cardiac 9	  
functionality, as defined by fractional ejection (EF) or fractional shortening (FS) parameters (Fig. 2d). Consistently, fibrosis was not 0	  
increased in either 4 or 9 month-old GRK2+/- mice compared with age-matched controls (Fig. 2e). 1	  
 2	  
3.3 Decreased GRK2 levels correlate with the expression of key genes involved in physiological hypertrophy/cardioprotection 3	  
Insulin is known to play a protective role in cardiac physiology, via the control of cardiac substrate utilization, cardiomyocyte 4	  
growth, gene expression, survival and contractility by means of the homeostatic stimulation of the PI3K/Akt and other intracellular 5	  
signalling pathways [17] . As an unbiased approach to assess the functional consequences of altering GRK2 levels in the modulation 6	  
of insulin response and heart function, we compared the transcriptional profile of the cardiac tissue of WT and GRK2+/- mice of 4 or 9 7	  
months of age using microarray RNA expression techniques without subjecting the animals to prior specific treatments to study the 8	  
integrated response of the tissue to homeostatic endogenous signals. Comparison of gene expression profiles between WT and 9	  
GRK2+/- animals at each group of age (database access number GSE41706) revealed significant differences only at 9 months (33 0	  
	   8	  
genes significantly up-regulated and 28 genes down-regulated in GRK2+/- mice compared to WT) while no differences between 1	  
genotypes were detected at 4 months of age (Figure 3a and Suppl. Table 1), suggesting that the effects of GRK2 dosage on cardiac 2	  
gene expression require additional age-related changes to become apparent.  3	  
We next performed a detailed analysis of the function and characteristics of the up or down-regulated genes. Several interesting 4	  
patterns were noted. First, GRK2+/- mice at 9 months of age showed decreased expression of genes described to be up-regulated during 5	  
pathological heart hypertrophy and/or in well-characterized cardiovascular disease co-morbidities such as diabetes and obesity. Eight 6	  
out of the 28 genes down-regulated in GRK2+/- mice (29%) belonged to this group (see Fig. 3b). This list included the pivotal heart 7	  
hypertrophy markers Acta1 (skeletal muscle alpha-actin) and the atrial natriuretic factor precursor Nppa [18, 19]; the cardiovascular 8	  
heat shock protein Hspb7, with high expression in ob/ob mice skeletal muscle [20] and polymorphisms associated with development 9	  
of idiopathic dilated cardiomyopathy and heart failure [21]; the transcription factor promyelocytic zing finger protein (Plzf, also 0	  
known as Zbtb16), a mediator of angiotensin 2-type 2 receptor-triggered cardiac hypertrophy [22];  the microfibril-associated 1	  
glycoprotein-2 (Magp-2, also known as Mfap5), an angiogenic stimulator upregulated in transgenic models of HF [23], or the tissue 2	  
inhibitor of metalloproteinase 4 (Timp4), a proposed marker for left ventricular remodelling and deteriorating HF [24]. Prostaglandin 3	  
D synthase (Ptgds), increased in the coronary circulation of angina patients [25] and overexpressed in type 2 diabetes [26] and the p85 4	  
alpha PI3K regulatory subunit (Pik3R1), enhanced in the myocardium of mice developing diet-induced obesity [27] and a key 5	  
negative regulator of insulin signaling [28, 29] were also decreased in 9 month-old GRK2+/- hearts.  6	  
 7	  
A second interesting pattern found in GRK2+/- mice was that 10 out of 33 genes that were up-regulated in these animals (30%) 8	  
have been reported to play a protective role in cardiovascular disease and are often down-regulated in pathological heart hypertrophy 9	  
and/or diabetes/obesity co-morbidities (Fig. 3b). In this regard, the expression of Ppargc1b, Hdac9, RRad, or Pde4b, reported as key 0	  
negative regulators of pathological heart hypertrophy, was enhanced in GRK2+/- mice. PGC1beta (Peroxisome proliferator-activated 1	  
receptor (PPAR)-gamma1beta co-activator) is essential for mitochondrial biogenesis and energy homeostasis. Decreased Ppargc1b 2	  
expression correlates with cardiac insufficiency and cardiomyopathy and with obesity and type-2 diabetes, whereas its genetic deletion 3	  
accelerates the transition to HF following pressure overload hypertrophy [30, 31]. HDAC9 is an inhibitor of pathological (but not 4	  
physiological) cardiac hypertrophy and Hdac9-deficient mice exhibit stress-dependent cardiomegaly [32]. RRAD (Ras associated with 5	  
diabetes GTPase) levels are decreased in human failing hearts and in animal and cellular models of cardiac hypertrophy, and RRad-6	  
deficient mice are more susceptible to this condition [33]. RRAD appears to prevent CAMK-II-dependent hypertrophy, to inhibit 7	  
cardiac fibrosis and to modulate beta-adrenergic mediated contractility [33, 34]. Phosphodiesterase 4B (PDE4B) is an important, 8	  
protective negative modulator of beta-adrenergic-mediated contractility with decreased levels in cardiac hypertrophy [35]. 9	  
Thrombospondin 1 (Thbs1), a protein that modulates extracellular matrix metabolism and fibroblast phenotype, suggested to act as a 0	  
protective signal in the stressed heart [36] was also enhanced in GRK2+/- mice, as was the anti-angiogenic homeobox gene Meox2 1	  
[37]. 2	  
The third relevant pattern of differential expression detected in GRK2+/- mice reflects changes in the expression of genes similar to 3	  
those taking place upon exercise and in situations of physiological heart hypertrophy (Fig. 3b). These include the up-regulation of the 4	  
central protective factors Ppargc1b and Nr4a1 (see above); the early response genes FosB and Apold 1, reported to be enhanced in 5	  
cardiac tissue upon acute physical activity [38] and the downregulation of the transcription factor C/EBPbeta (Cebpb), a member of 6	  
the bHLH family. Importantly, the latter has been recently identified as a master regulator of physiological cardiac hypertrophy [39, 7	  
40]. The mRNA expression of C/EBPbeta is reduced circa 60% (in the same range of our data) in mouse hearts in an exercise model 8	  
allowing expression of an adaptive gene profile related to physiological hypertrophy, and mice with reduced cardiac levels of this 9	  
	   9	  
protein displayed resistance to cardiac failure upon pressure overload [39]. The expression profile of several of the key genes 0	  
supporting these patterns was validated by qPCR (Suppl. Fig. 2S). 1	  
In sum, the microarray analysis detected in GRK2+/- mice hearts an increased expression of a limited group of important genes 2	  
related to physiological hypertrophy while the expression of genes key to the development of pathological hypertrophy or related to 3	  
diabetes/obesity co-morbidities is repressed. 4	  
3.4 Increased cardiac GRK2 expression in adult obese (ob/ob) mice and in high fat diet-fed animals 5	  
Since GRK2 levels increase in muscle and adipose tissue under insulin resistance-promoting conditions [2] we tested whether this 6	  
process was also taking place in cardiac tissue. A clear increase in GRK2 protein levels was observed in hearts of 8 month-old ob/ob 7	  
mice (Fig. 4a), an age in which this strain of mice is known to manifest cardiac hypertrophy, IR and metabolic alterations involving 8	  
alterations in the PI3K/Akt axis [41]. This increase in total GRK2 protein levels caused an increment in the amount of GRK2 that 9	  
could be detected in association with IRS1 (Fig. 4b), a situation that we have previously described to negatively modulate insulin 0	  
signaling. GRK2 levels were also increased upon feeding young animals a high fat diet (HFD, Fig. 4c), a well-established trigger for 1	  
systemic IR that can promote cardiac remodeling and dysfunction and known to disrupt the insulin-stimulated IRS1/PI3K/Akt cascade 2	  
[42]. This increase is similar to that observed in other insulin-sensitive tissues [2], and also had as a consequence a larger amount of 3	  
formation of IRS1-GRK2 complexes (Fig. 4d). We investigated insulin responses in cardiac tissue of WT and GRK2+/- HFD-fed 4	  
animals. Figure 4e-f shows that sensitivity to insulin is compromised in WT hearts after HFD feeding, while it is strongly preserved in 5	  
GRK2+/- hearts, in the absence of changes in insulin-induced ERK phosphorylation. Together these results suggest that the increase in 6	  
GRK2 protein levels observed upon HFD feeding or genetically-induced obesity promotes GRK2-dependent sequestration of IRS1 7	  
and provides a mechanistic explanation for the IR state of cardiac tissue in both experimental conditions. 8	  
4. DISCUSSION	  9	  
	  0	  
We have addressed herein the potential interconnections among an IR status, GRK2 dosage and cardiac remodeling by 1	  
investigating the impact of GRK2 down-modulation on cardiac insulin sensitivity and gene expression patterns, and the effects of 2	  
systemic insulin resistance-promoting conditions on cardiac GRK2 levels.   3	  
First, we find that decreased GRK2 levels specifically preserve metabolic and pro-survival signals downstream of insulin (such as 4	  
the Akt/p70S6K pathway and glucose transport) in the hearts of 9 month-old GRK2+/- animals, whereas the ERK activation status is 5	  
not affected. Second, with age, GRK2 down-regulation triggers physiological heart hypertrophy and switches on a cardioprotective 6	  
gene expression pattern as detected in such adult mice. This pattern is characterized by an increased expression of a limited group of 7	  
key genes related to physiological hypertrophy, while the expression of genes reported to lead to the development of pathological 8	  
hypertrophy or related to diabetes/obesity co-morbidities is repressed, compared to WT individuals. Third, we uncover that cardiac 9	  
GRK2 expression levels increase in situations of systemic insulin resistance, such as in obese mice or after HFD feeding, conditions in 0	  
which larger amounts of GRK2-IRS1 complexes are formed. Fourth, while insulin resistance develops in the hearts of wild-type mice 1	  
after HFD feeding, sensitivity to insulin was strongly preserved in GRK2+/- cardiac tissue. 2	  
We have previously reported that GRK2+/- mice are protected against HFD-induced obesity and systemic IR, and we cannot rule 3	  
out that this global protection may contribute to the observed enhanced insulin signaling in the heart upon a HFD. However, given the 4	  
enhanced interaction of GRK2 with IRS1 that we find in cardiac tissue of different obese mice models, our data point at an important 5	  
role for this kinase in negatively regulating insulin signaling in the heart, coherent with what was previously published by Garcia-6	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Guerra et al. [2] involving the sequestration of IRS1 protein in GRK2 complexes thus impairing downstream signalling from the 7	  
insulin receptor. 8	  
 Previous reports have determined the importance of insulin signalling in cardiac physiopathology [43].	   In particular, results in 9	  
cardiomyocyte-specific deletion of the insulin receptor (CIRKO mice) have revealed that insulin can control cardiac gene expression 0	  
patterns since loss of its receptor promotes a genomic reprogramming [44]. Insulin signals also control the size of the heart and 1	  
cardiomyocytes, and deletion of insulin receptor decreases cardiac size by 20-30% [45].	  These results are in agreement with the 2	  
phenotype we find in GRK2 hemizygous mice in which the increased sensitivity for insulin signals results in gene expression 3	  
reprogramming and an increased cardiac size. 4	  
The fact that GRK2 downregulation potentiates the insulin-triggered PI3K/Akt pathway in the adult mice heart is then consistent 5	  
with the mild hypertrophic phenotype conferred by age to GRK2+/- animals being physiological rather than pathological, This is in 6	  
agreement with the morphometric analysis and functional results, and with an overall cardio-protective gene expression pattern 7	  
(decreased presence of pathological genes, enhanced expression of critical protective genes) in the heart of GRK2+/- 9 month-old mice. 8	  
It is worth noting that GRK2+/- animals displayed changes in the expression of several genes reported to be similarly modulated by 9	  
insulin in the heart or other tissues (Nr4a1, Tcfl2, Rrad, Aqp7, Cebpb, Ppargc1b, Egr1), and a relevant proportion of genes whose 0	  
expression is altered in hemizygous animals can be related to: i) the modulation of insulin sensitivity; ii) to the PI3K/Akt pathway; iii) 1	  
to diabetes/obesity-related pathological situations.  2	  
Insulin activation of the PI3K/Akt cascade is protective in the heart by inhibiting apoptosis and oxidative stress [46], whereas 3	  
myocardial IR has been suggested as a key factor in the development of HF [47, 48]. In this context, our results strongly suggest the 4	  
novel concept that cardiac GRK2 levels could act as an integrative sensor of different pathological inputs and affect cardiac function 5	  
by simultaneously altering beta-adrenergic and insulin signalling (see suggested model in Fig. 5). Thus, the increase in cardiac GRK2 6	  
levels previously reported to take place in myocardial infarction or hypertension as a consequence of excessive neurohormonal 7	  
stimulation [5, 6], would also take place as a consequence of insulin resistance-promoting conditions such as a HFD or obesity, by 8	  
mechanisms that remain to be investigated. Also, enhanced cardiac GRK2 would promote, in addition to the canonical effects 9	  
described for GPCR signaling, an insulin-resistant state of the heart leading to alterations of key metabolic and cardioprotective 0	  
pathways [11], further fuelling a dysfunctional cycle and allowing progression to maladaptive remodelling.  1	  
A detrimental vicious cycle has been postulated [48, 49] in which the compensatory hyper-adrenergic state characteristic of 2	  
reduced cardiac output would promote lipolysis in the adipose tissue. This would lead to increased circulating levels of free fatty 3	  
acids, what in turn would inhibit cardiac glucose transport, switching energy substrate use and triggering heart lipotoxicity. 4	  
Conversely, many mechanisms have been suggested to explain the increased incidence of HF in diabetic patients, including 5	  
hyperinsulinemia, hyperglycemia, lipotoxicity, obesity, vascular alterations, increased oxidative stress or hyperactivation of 6	  
neurohumoral systems ([47, 48, 50] and references therein). Our data suggest that GRK2 could participate as an important integrative 7	  
node in such complex mechanisms linking HF, diabetes and IR. 8	  
Such central role of GRK2 also fosters its potential as a therapeutic target and diagnostic marker. Our study suggests that strategies 9	  
leading to a systemic reduction in GRK2 levels/function, even when used in a sustained temporal frame and in adult tissue, could 0	  
facilitate the activation of defined cardioprotective routes, such as the insulin pathway. This would promote a physiological 1	  
hypertrophy-like gene expression pattern that could contribute to explain the beneficial outcome of GRK2 inhibition.  2	  
 3	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This discovery could help explain the reported reinforcement between the therapeutic effects of down-regulating cardiac 4	  
adrenergic input (using beta-blockers) and GRK2 down-modulation.  5	  
Since our data and previous report by other laboratories [1, 6, 7]	   indicate that reduced GRK2 revels are beneficial for cardiac 6	  
function and also for maintaining vascular tone [4],	  and systemic insulin sensitivity [2], it could be argued that GRK2 hemizygosity 7	  
would confer an overall benefit. However, the fact that a GRK2+/+ genotype has been positively selected for by evolution suggest that 8	  
the expression level generated by such genotype must be overall adaptative. Nevertheless, unlimited food availability, a condition that 9	  
humans nowadays share with caged animals, was not at all present during evolution and therefore this might explain why GRK2 0	  
downregulation was not selected for.   1	  
GRK2 inhibition has been shown, in mouse models, to delay the reduction in glucose uptake and preserve insulin signalling in the 2	  
heart after myocardial ischemia [11] and to prevent the development of systemic IR [2]. It is also worth noting that, apart from its 3	  
catalytic kinase activity (target for potential GRK2 inhibitors), GRK2 plays an important functional role via protein-protein 4	  
interactions. Our gene expression data cannot dissect which biological function of GRK2 needs to be reduced for therapeutic purposes, 5	  
and it could well be possible that inhibition of the enzymatic activity of GRK2 might not reproduce the beneficial effects observed 6	  
upon its under-expression. Thus, a better knowledge of means to reduce GRK2 levels in vivo, such as increasing its degradation rate or 7	  
decreasing transcription, should be built before an effective GRK2 downmodulation therapy can be designed. Interestingly, ventricular 8	  
assist device implantation, known to downregulate GRK2 levels [51], also reverses IR and normalizes cardiac metabolism in patients 9	  
with advanced HF[52]. This is consistent with a beneficial role for GRK2 inhibition in this context. Notably, the reduction in GRK2 0	  
protein levels observed in lymphocytes of HF patients after an exercise-training program can predict long-term survival [53]. On the 1	  
other hand, enhanced GRK2 levels in peripheral lymphocytes mimic myocardial levels during hypertension, myocardial ischemia and 2	  
heart failure [6] and are also increased in patients with metabolic syndrome [2]. Therefore, it will be interesting to explore the 3	  
potential use of GRK2 as a prognostic cardiovascular risk marker when co-morbidities as diabetes, IR and obesity are present. 4	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Figure 1                                                                             Lucas and Jurado-Pueyo et al 
 
Figure 1. GLUT4 translocation to the membrane and insulin signalling are upregulated in hearts from adult 
GRK2+/- mice. a). GLUT4 translocation in the plasma membrane fraction after an intravenous injection of insulin for 25 
minutes in 9 month-old WT and GRK2+/- mice (N=6-8 per genotype). Results were normalized to Caveolin 3 levels and 
are expressed as fold increase over basal (non-insulin treated mice). Representative blots are  shown including α-Tubulin 
blot as an indicator of  the absence of cytosolic contamination. Quantification of Akt phosphorylation (Ser473) (b) and 
p70S6K phosphorylation (Thr389) (c) in the cardiac tissue lysates of WT or GRK2+/- 9 month-old mice after an 
intravenous injection of insulin for 3 or 5 minutes (N=3-5). Results are expressed as fold increase over control (non-
insulin treated mice). d) Representative Western Blots of the specified phospho-proteins and controls in heart tissue 3 or 5 
min after insulin injection. Data are mean±SEM of the indicated independent experiments. ***,p<0.001; *,p<0.05 
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Figure 2                                                                             Lucas and Jurado-Pueyo et al 
 
Figure 2. GRK2+/- 9 month-old mice show mild, non-pathological heart hypertrophy. a) Heart weight 
(mg) to body weight (g) ratio in 4 and 9 month-old WT and GRK2+/- mice (N=7-14). b) Total area of cross 
sections of each heart was measured from high-resolution images using the AnalySIS® software and 
expressed in mm2 for WT (white bars) and GRK2+/- (black bars) mice (N=5-9). c) Cardiomyocyte diameter (in 
µm) was measured in the cross-section of cells perpendicular to the slices stained with Masson´s Trichrome in 
at least 20 cells per sample using the AnalySIS® software (N=5-9). d) Fold change of ejection fraction (EF) 
and fractional shortening (FS), with statistical analysis performed using T- test. e) Quantification of the 
fibrotic area of heart cross sections stained with Syrius Red, digitalized using the Axiovision software and 
analyzed using the AnalySIS® software. Representative pictures are shown when applicable. Data are 
mean±SEM of the indicated independent experiments *, p<0.05 
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Figure 3                                                                                  Lucas and Jurado-Pueyo et al 
 
Figure 3. Comparison of cardiac gene expression profiles between young (4 month-old) or adult (9 
month-old) WT and GRK2+/- mice. a) Genes whose expression varied significantly between WT and 
GRK2+/- mice are represented. Pairwise analyses were performed and visualized using the FIESTA viewer for 
an FDR<0.2 (Fold change >1.5 or <-1.5). No genes were found to change significantly at 4 months of age, 
but, at 9 months of age, 61 genes were significantly different between WT and GRK2+/- mice. Black, genes 
whose expression is increased in GRK2+/- vs WT. Grey, genes whose expression is reduced in GRK2+/- vs 
WT. b) The table depicts genes reported to be upregulated during pathological heart hypertrophy or during 
comorbidities such as diabetes/obesity (see references in the text) found to be downregulated in adult GRK2+/- 
mice vs WT heart microarray, or genes for which the inverse relationship occurs (left panel). Also, a list of 
genes upregulated/downregulated in the array and also during physiological heart hypertrophy or response to 
exercise is specified (right panel). 
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Figure 4                                                                                 Lucas and Jurado-Pueyo et al 
 
 
Figure 4. Expression of the GRK2 protein is increased in myocardial tissue of obese or high fat diet-fed 
mice which correlates with higher levels of IRS1/GRK2 complexes, whereas GRK2+/- animals are 
resistant to high fat diet-induced insulin resistance in cardiac tissue. a) The expression levels of GRK2 
were analyzed by Western Blot in cardiac tissue of 8 month-old ob/ob or WT mice and quantified by 
densitometry analysis. Results were normalized by GAPDH protein levels and expressed as percent over 
control (WT mice) (N= 5). b) Total protein from heart tissue (500 µg) was immunoprecipitated with the anti-
IRS1 or anti-IgG antibodies, and the resulting immune complexes were analyzed by Western blot with the 
corresponding antibodies against GRK2 and IRS1.(N=3). Precipitated GRK2 amount was normalized with 
immunoprecipitated IRS1 amount. Same for 3 month-old HFD-fed mice represented  over standard diet-fed 
animals in (c) and (d) (N= 9). Representative blots are shown. Data are mean±SEM of the indicated 
independent experiments *,p<0.05; **,p<0.01. e) Representative Western Blots of the specified phospho-
proteins and controls in heart tissue after 12 weeks of HFD feeding or SD and 3 min insulin injection in WT 
or GRK2+/- mice. (f) Quantification of Akt phosphorylation (Ser473),  p70S6K phosphorylation (Thr389) or 
ERK1/2 phosphorylation (Thr202/Tyr204) in cardiac tissue lysates of WT and GRK2+/- mice after 12 weeks 
of HFD feeding after an intravenous injection of insulin for 3 minutes (N= 3-4). Results are expressed as fold 
increase over basal (untreated mice). Statistical analysis was performed using T-test. Data are mean±SEM of 
the indicated independent experiments.+++p<0.001;+p<0.05 referred to basal (untreated mice); **p<0.01; 
*p<0.05 referred to fold increase upon insulin stimulation over HFD fed WT mice. 
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Figure 5                                                                                 Lucas and Jurado-Pueyo et al 
 
 
Figure 5. Schematic representation of the proposed model of GRK2 up-regulation linking insulin-
resistance and maladaptive cardiac remodeling. Increased GRK2 as a result of different pathophysiological 
situations would not only lead to a decrease in β-AR responsiveness, but also in insulin signaling thus 
promoting a pathological increase in the neurohumoral stimulation of the heart, and also lead to IR thus 
aggravating this condition. GRK2-promoted transcription reprogramming would also impinge upon both 
processes.  
 2 
Supplemental Table 1S. Detailed list of genes showing differential expression 
between WT and GRK2+/- adult hearts. 
SUPPLEMENTAL TABLES AND FIGURES 
Genes whose expression varied with an FDR<0.2 and a Fold change >1.5 or <-1.5 are 
listed.  
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Supplemental Figure 1S 
 
 
 
Suppl. Fig.1S.- Glucose uptake and insulin signalling are upregulated in hearts 
from adult GRK2+/- mice without differences in pERK activation. a) Positron 
emission tomography (PET) analysis of insulin-dependent 18F-Fluoro deoxy-glucose 
uptake in the hearts of 9 month-old WT and GRK2+/- mice (N=3 per genotype). 
Quantification of IRS1 phosphorylation (Tyr896) (b) and ERK1/2 phosphorylation 
(Thr202/Tyr204) (c) in the cardiac tissue lysates of WT or GRK2+/- 9 month-old mice 
after an intravenous injection of insulin for 3 or 5 minutes (N=3-5). Results are 
expressed as fold increase over control (non-insulin treated mice). d) Representative 
Western Blots of the specified phospho-proteins and controls in heart tissue 3 or 5 min 
after insulin injection. Data are mean±SEM of the indicated independent experiments.  
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Supplemental Figure 2S 
 
Suppl. Fig.2S.- Validation by qRT-PCR analysis. A qRT-PCR analysis was performed 
for certain genes whose changes in expression are described to correlate with 
physiological or pathological cardiac hypertrophy or other cardiac responses important 
for cardiac physiopathology as discussed in the main text. * p<0.05, # 0.2>p>0.05. 
 
